deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05453396

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

A Pilot Study of Loncastuximab Tesirine in Specific Populations of Relapsed/Refractory B-Cell Malignancies

Sponsor: University of Washington

Conditions Post-Transplant Lymphoproliferative Disorder Recurrent B-Cell Non-Hodgkin Lymphoma Recurrent Diffuse Large B-Cell Lymphoma Recurrent Follicular Lymphoma Recurrent Mantle Cell Lymphoma Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder Refractory B-Cell Non-Hodgkin Lymphoma Refractory Diffuse Large B-Cell Lymphoma Refractory Follicular Lymphoma Refractory Mantle Cell Lymphoma Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
Interventions Loncastuximab Tesirine
Updated 15 times since 2022 Last updated: Oct 14, 2025 Started: Aug 7, 2023 Primary completion: Dec 15, 2026 Completion: Jul 6, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05453396, this PHASE2 trial focuses on Post-Transplant Lymphoproliferative Disorder and Recurrent B-Cell Non-Hodgkin Lymphoma and remains actively recruiting participants. Sponsored by University of Washington, it has been updated 15 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Feb 2023 · 2 months · monthly snapshot~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshot~Apr 2023 – ~May 2023 · 30 days · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~Jul 2023 · 30 days · monthly snapshot~Jul 2023 – ~Sep 2023 · 2 months · monthly snapshot~Sep 2023 – ~Nov 2023 · 2 months · monthly snapshot~Nov 2023 – ~May 2024 · 6 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~May 2025 · 6 months · monthly snapshot~May 2025 – ~Nov 2025 · 6 months · monthly snapshot~Nov 2025 – present · 9 months · monthly snapshot

Change History

15 versions recorded

  1. Nov 2025 — Present [monthly]

    Recruiting PHASE2

  2. May 2025 — Nov 2025 [monthly]

    Recruiting PHASE2

  3. Nov 2024 — May 2025 [monthly]

    Recruiting PHASE2

  4. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

▶ Show 10 earlier versions

  1. May 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

  2. Nov 2023 — May 2024 [monthly]

    Recruiting PHASE2

  3. Sep 2023 — Nov 2023 [monthly]

    Recruiting PHASE2

  4. Jul 2023 — Sep 2023 [monthly]

    Recruiting PHASE2

  5. Jun 2023 — Jul 2023 [monthly]

    Recruiting PHASE2

  6. May 2023 — Jun 2023 [monthly]

    Recruiting PHASE2

  7. Apr 2023 — May 2023 [monthly]

    Recruiting PHASE2

  8. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Dec 2022 — Feb 2023 [monthly]

    Not Yet Recruiting PHASE2

  10. Sep 2022 — Dec 2022 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • University of Washington
Data source: University of Washington

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations